Richard B. Kim

27.6k total citations · 4 hit papers
243 papers, 18.5k citations indexed

About

Richard B. Kim is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Richard B. Kim has authored 243 papers receiving a total of 18.5k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Oncology, 82 papers in Pediatrics, Perinatology and Child Health and 70 papers in Pharmacology. Recurrent topics in Richard B. Kim's work include Drug Transport and Resistance Mechanisms (112 papers), Pharmacogenetics and Drug Metabolism (66 papers) and Pharmacological Effects and Toxicity Studies (66 papers). Richard B. Kim is often cited by papers focused on Drug Transport and Resistance Mechanisms (112 papers), Pharmacogenetics and Drug Metabolism (66 papers) and Pharmacological Effects and Toxicity Studies (66 papers). Richard B. Kim collaborates with scholars based in Canada, United States and Germany. Richard B. Kim's co-authors include Brenda F. Leake, Rommel G. Tirona, G. Wilkinson, Ute I. Schwarz, Martin F. Fromm, Wooin Lee, C. Michael Stein, Dan M. Roden, Alastair J.J. Wood and George K. Dresser and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Richard B. Kim

236 papers receiving 17.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

1998 910 citations Richard B. Kim, Martin F. Fromm et al. profile →
SLC transporters as therapeutic targets: emerging opportunities

2015 584 citations Richard B. Kim et al. profile →
OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine

1999 500 citations Brenda F. Leake, Martin F. Fromm et al. Drug Metabolism and Disposition profile →
Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics

2006 500 citations Richard Ho, Rommel G. Tirona et al. profile →

Peers

Countries citing papers authored by Richard B. Kim

Since Specialization

Citations

This map shows the geographic impact of Richard B. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard B. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard B. Kim more than expected).

Fields of papers citing papers by Richard B. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard B. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard B. Kim. The network helps show where Richard B. Kim may publish in the future.

Co-authorship network of co-authors of Richard B. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Richard B. Kim. A scholar is included among the top collaborators of Richard B. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard B. Kim. Richard B. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NFIB rs28379954 does not affect CYP2D6-mediated metabolism of prototypical substrates, tamoxifen or solanidine 2025 ·Pharmacogenetics and Genomics ·(unknown), Ute I. Schwarz, Richard B. Kim	0
2	SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin‐induced rhabdomyolysis: A case report 2024 ·British Journal of Clinical Pharmacology ·(unknown), (unknown), Steven E. Gryn, Richard B. Kim	1
3	Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis 2023 ·The European Journal of Health Economics ·(unknown), Ute I. Schwarz, Guangyong Zou, Eric McArthur, Richard B. Kim, Amit X. Garg, Sisira Sarma	2
4	Thiopurine Methyltransferase Intermediate Metabolizer Status and Thiopurine‐Associated Toxicity During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia 2023 ·Clinical Pharmacology & Therapeutics ·Ute I. Schwarz, (unknown), (unknown), (unknown), Chantel Cacciotti, Elizabeth Cairney, (unknown), (unknown), Soumitra Tole, Marta Wilejto, Rommel G. Tirona, Richard B. Kim, (unknown)	2
5	Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada 2023 ·PharmacoEconomics ·(unknown), Lauren E. Cipriano, Richard B. Kim, Gregory S. Zaric, Ute I. Schwarz, Sisira Sarma	1
6	Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn’s disease 2020 ·Scientific Reports ·Aze Wilson, (unknown), Wendy A. Teft, Richard B. Kim	53
7	HLADQA105* genotype predicts anti‐drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease 2019 ·Alimentary Pharmacology & Therapeutics ·Aze Wilson, (unknown), Qian Wang, (unknown), Richard B. Kim	63
8	Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients 2018 ·Oral Oncology ·Wendy A. Teft, Eric Winquist, Anthony C. Nichols, Sara Kuruvilla, Suzanne Richter, Christina Parker, P. Francis, (unknown), (unknown), Nedal Bukhari, Yun‐Hee Choi, Stephen Welch, David A. Palma, John Yoo, Richard B. Kim	30
9	Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance 2015 ·Molecular Cancer Therapeutics ·(unknown), Brenda F. Leake, Wendy A. Teft, Rommel G. Tirona, Richard B. Kim, Richard Ho	33
10	Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance. 2013 ·PubMed ·Leslie Skeith, Cory Yamashita, Sanjay Mehta, (unknown), Richard B. Kim	11
11	Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation 2011 ·PLoS ONE ·Inna Y. Gong, Ute I. Schwarz, Natalie Crown, George K. Dresser, Alejandro Lazo‐Langner, Guangyong Zou, Dan M. Roden, C. Michael Stein, Marc Rodger, Philip S. Wells, Richard B. Kim, Rommel G. Tirona	62
12	Durable Complete Response of Refractory, Progressing Metastatic Melanoma After Treatment with a Patient-Specific Vaccine 2010 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, (unknown), (unknown), Richard B. Kim, (unknown), (unknown), (unknown), Christopher Duma, (unknown), Senthamil R. Selvan, Andrew N. Cornforth, Carol DePriest	18
13	Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1) 2010 ·Drug Metabolism and Disposition ·Wendy A. Teft, Sara E. Mansell, Richard B. Kim	57
14	Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins 2009 ·Circulation Research ·Michael J. Knauer, Bradley L. Urquhart, Henriette E. Meyer zu Schwabedissen, Ute I. Schwarz, (unknown), Brenda F. Leake, Richard B. Kim, Rommel G. Tirona	176
15	Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity 2008 ·Cancer Research ·Partha Krishnamurthy, Matthias Schwab, Kazumasa Takenaka, Deepa Nachagari, James P. Morgan, (unknown), Weinan Du, Kelli L. Boyd, Meyling Cheok, Hiromitsu Nakauchi, Catia Marzolini, Richard B. Kim, Poonkuzhali Balasubramanian, Erin G. Schuetz, William E. Evans, Mary V. Relling, John D. Schuetz	116
16	Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study 2006 ·Clinical Infectious Diseases ·Heather J. Ribaudo, David W. Haas, C. Tierney, Richard B. Kim, G. Wilkinson, Roy M. Gulick, David B. Clifford, Catia Marzolini, Courtney V. Fletcher, Karen T. Tashima, Daniel R. Kuritzkes, Edward P. Acosta	170
17	Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity 2006 ·Clinical Infectious Diseases ·Marylyn D. Ritchie, David W. Haas, Alison A. Motsinger‐Reif, John P. Donahue, (unknown), Stephen Raffanti, Peter F. Rebeiro, Alfred L. George, Richard B. Kim, J.L. Haines, T. R. Sterling	73
18	MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV-1 Infection 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·David W. Haas, Hulin Wu, Haihong Li, Ronald J. Bosch, Michael M. Lederman, Daniel R. Kuritzkes, Alan Landay, Elizabeth Connick, Constance A. Benson, G. Wilkinson, Harold A. Kessler, Richard B. Kim	49
19	The Anthelminthic Agent Albendazole Does Not Interact with P-Glycoprotein 2002 ·Drug Metabolism and Disposition ·Gracia Merino, Ana I. Álvarez, Julio G. Prieto, Richard B. Kim	38
20	Human MRP3 transporter: identification of the 5′-flanking region, genomic organization and alternative splice variants1The GenBank accession numbers of MRP3 and its splice variants MRP3A and MRP3B described in this paper are AF085690, AF085691 and AF085692, respectively.1 1999 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·Martin F. Fromm, Brenda F. Leake, Dan M. Roden, G. Wilkinson, Richard B. Kim	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact